Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 9/20 | 0.47 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.31 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6917356 | 0.78 | CHRM1 (0.64) | CHRM1 | |
| SCHEMBL6912925 | 0.64 | CHRM1 (1.00) | CHRM1 | |
| SCHEMBL8836603 | 0.62 | CHRM1 (0.57) | CHRM1 | |
| SCHEMBL27550878 | 0.62 | CHRM1 (0.57) | CHRM1 | |
| SCHEMBL6942731 | 0.61 | PAK1 (0.33) | — | |
| SCHEMBL12649074 | 0.55 | — | — | |
| Hydrochloric Acid SCHEMBL1769144 | 0.53 | CHRM1 (0.45) | CHRM1 | |
| SCHEMBL7517327 | 0.53 | GBA1 (0.53) | CHRM1 | |
| SCHEMBL92505 | 0.53 | — | — | |
| SCHEMBL8445611 | 0.52 | CHRM1 (0.42) | CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5998434-A | Composition for treating pain | ELI LILLY AND COMPANY (US) | 1999-12-07 | — | — | US | claimed |
| EP-0874828-A4 | COMPOSITION FOR TREATING PAIN | LILLY CO ELI (US) | 1999-09-01 | — | — | EP | claimed |
| EP-0874828-A1 | COMPOSITION FOR TREATING PAIN | ELI LILLY AND COMPANY (US) | 1998-11-04 | — | — | EP | claimed |
| WO-1997020819-A1 | COMPOSITION FOR TREATING PAIN | ELI LILLY AND COMPANY (US) | 1997-06-12 | — | — | WO | claimed |
| US-20040023951-A1 | Combination therapy for treatment of psychoses | ELI LILLY AND COMPANY | 2004-02-05 | — | — | US | disclosed |
| US-6194416-B1 | CENTRAL NERVOUS SYSTEM DISORDERS; ALZHEIMER'S DISEASE | ELI LILLY AND COMPANY | 2001-02-27 | — | — | US | disclosed |
| US-6187776-B1 | AZACYCLIC-SUBSTITUTED PYRIDINE DERIVATIVES; ALZHEIMER*S DISEASE, SCHIZOPHRENIA, GASTROINTESTINAL DISORDERS; COGNITION ACTIVATORS | ELI LILLY AND COMPANY | 2001-02-13 | — | — | US | disclosed |
| EP-0788489-A4 | HETEROCYCLIC COMPOUNDS AND THEIR USE | LILLY CO ELI (US) | 2000-11-15 | — | — | EP | disclosed |
| US-6071900-A | 2-AZABICYCLOOXYPYRIDAZINES TO TREAT DISEASES IN THE CENTRAL NERVOUS SYSTEM CAUSED BY MALFUNCTIONING OF THE MUSCARINIC CHOLINERGIC SYSTEM; ALZHEIMER'S DISEASE; ANALGESICS; GI AND SLEEPING DISORDERS; GLAUCOMA, PSYCHOSIS, ANTIDEPRESSANTS | ELI LILLY AND COMPANY (US) | 2000-06-06 | — | — | US | disclosed |
| US-6030966-A | FOR TREATING ALZEHIMER'S DISEASE | ELI LILLY AND COMPANY (US) | 2000-02-29 | — | — | US | disclosed |
| US-5998404-A | NERVOUS SYSTEM DISORDERS | ELI LILLY AND COMPANY (US) | 1999-12-07 | — | — | US | disclosed |
| US-5998434-A | Composition for treating pain | ELI LILLY AND COMPANY (US) | 1999-12-07 | — | — | US | disclosed |
| EP-0874828-A1 | COMPOSITION FOR TREATING PAIN | ELI LILLY AND COMPANY (US) | 1998-11-04 | — | — | EP | disclosed |
| US-5763457-A | ADMINISTERING TO THE PATIENT SUFFERING FROM ANXIETY DISORDER AN OXADIZOLE COMPOUND | ELI LILLY AND COMPANY (US) | 1998-06-09 | — | — | US | disclosed |
| EP-0788489-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE | ELI LILLY AND COMPANY (US) | 1997-08-13 | — | — | EP | disclosed |
| WO-1997020819-A1 | COMPOSITION FOR TREATING PAIN | ELI LILLY AND COMPANY (US) | 1997-06-12 | — | — | WO | disclosed |
| WO-1997017956-A1 | METHOD FOR TREATING ANXIETY | ELI LILLY AND COMPANY (US) | 1997-05-22 | — | — | WO | disclosed |
| EP-0773021-A1 | Use of azacyclic or azabicyclic oxadiazole compounds for treating anxiety | ELI LILLY AND COMPANY (US) | 1997-05-14 | — | — | EP | disclosed |
| US-5605908-A | TREATING DISEASES OF CENTRAL NERVOUS SYSTEM CAUSED BY MALFUNCTIONING OF MUSCARINIC CHOLINERGIC SYSTEM | ELI LILLY AND COMPANY (US) | 1997-02-25 | — | — | US | disclosed |
| WO-1996012711-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE | ELI LILLY AND COMPANY (US) | 1996-05-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040023951-A1 | Combination therapy for treatment of psychoses | CHRM5, CHRM4, CHRM2 | CHRM1 8/4885CHRM2 3/4885CHRM3 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.